HK1218893A1 - 蛋白質的生產方法 - Google Patents

蛋白質的生產方法

Info

Publication number
HK1218893A1
HK1218893A1 HK16106899.1A HK16106899A HK1218893A1 HK 1218893 A1 HK1218893 A1 HK 1218893A1 HK 16106899 A HK16106899 A HK 16106899A HK 1218893 A1 HK1218893 A1 HK 1218893A1
Authority
HK
Hong Kong
Prior art keywords
production method
protein production
protein
production
Prior art date
Application number
HK16106899.1A
Other languages
English (en)
Inventor
Ela Puchacz
James Russel Grove
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of HK1218893A1 publication Critical patent/HK1218893A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
HK16106899.1A 2013-03-26 2016-06-15 蛋白質的生產方法 HK1218893A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805215P 2013-03-26 2013-03-26
US201461933665P 2014-01-30 2014-01-30
PCT/US2014/031883 WO2014160790A1 (en) 2013-03-26 2014-03-26 Protein production method

Publications (1)

Publication Number Publication Date
HK1218893A1 true HK1218893A1 (zh) 2017-03-17

Family

ID=51621470

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106899.1A HK1218893A1 (zh) 2013-03-26 2016-06-15 蛋白質的生產方法

Country Status (12)

Country Link
US (2) US9765139B2 (zh)
EP (2) EP3391942A1 (zh)
JP (2) JP6689189B2 (zh)
KR (1) KR20150133833A (zh)
AU (2) AU2014241259B9 (zh)
BR (1) BR112015024755A2 (zh)
CA (1) CA2907771C (zh)
HK (1) HK1218893A1 (zh)
MX (2) MX362922B (zh)
RS (1) RS59328B1 (zh)
SG (2) SG11201507875RA (zh)
WO (1) WO2014160790A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
MA50911A (fr) * 2017-11-13 2020-09-23 Amgen Inc Procédés de production de produits protéiniques
CN109971705A (zh) * 2019-04-16 2019-07-05 上海汉尼生物细胞技术有限公司 一种cho dg44细胞培养基添加物及其制备方法
JP2024503239A (ja) * 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2817235A (en) 1954-03-22 1957-12-24 Phillips Petroleum Co Temperature measuring system for underground storage cavern
US2893211A (en) 1955-05-16 1959-07-07 Phillips Petroleum Co Underground storage system
US3064436A (en) 1955-10-27 1962-11-20 Robert L Loofbourow Sealing underground cavities
DE1126800B (de) 1958-03-17 1962-03-29 Stamicarbon Vorrichtung zum Hinaufbefoerdern grobkoernigen Gutes, wie Erz und Kohle, aus grosser Teufe, z.B. aus einer Zeche od. dgl., mittels einer Transportfluessigkeit
US3068654A (en) 1958-09-22 1962-12-18 Interstate Service Corp Underground storage cavern and method of making same
US3184922A (en) 1960-07-12 1965-05-25 Suburban Propane Gas Corp Method of and means for storing liquefied petroleum gases underground
US4011736A (en) 1975-11-12 1977-03-15 Halm Instrument Co., Inc. Cold storage tank
FR2372751A1 (fr) 1976-12-02 1978-06-30 Commissariat Energie Atomique Reservoir souterrain pour fluides sous pression
SE450509B (sv) 1981-08-07 1987-06-29 Karl Ivar Sagefors Metod att bygga en anleggning for lagring av flytande produkter i berg
WO1983004455A1 (en) 1982-06-09 1983-12-22 John Canevall Procedure for permanently storing radioactive material
US4488834A (en) 1982-11-17 1984-12-18 Empak, Inc. Method for using salt deposits for storage
FR2545067B1 (fr) 1983-04-26 1987-08-07 Geostock Procede et dispositif de stockage souterrain d'ammoniac et produits analogues
US5207530A (en) 1992-07-29 1993-05-04 Halliburton Company Underground compressed natural gas storage and service system
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
US6826911B2 (en) 2001-03-12 2004-12-07 Pomfret Storage Company, Llc Storage of energy producing fluids and process thereof
MXPA05000552A (es) 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
DK1720972T3 (da) * 2004-03-05 2014-04-14 Dsm Ip Assets Bv Fremgangsmåde til celledyrkning ved hjælp af fortløbende perfusion og vekslende tangentialt flow
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
DK1885753T3 (da) * 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
SI1957630T2 (sl) * 2005-12-08 2023-07-31 Amgen Inc. Izboljšana proizvodnja glikoproteinov z uporabo mangana
EP2115126B1 (en) * 2007-03-02 2015-04-08 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011116148A2 (en) 2010-03-16 2011-09-22 Dana Todd C Systems, apparatus and methods for extraction of hydrocarbons from organic materials
CN102382794B (zh) * 2010-09-01 2013-09-18 山东新时代药业有限公司 一种哺乳动物细胞的灌流培养方法
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2952347A1 (en) * 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada

Also Published As

Publication number Publication date
WO2014160790A1 (en) 2014-10-02
KR20150133833A (ko) 2015-11-30
MX2019002183A (es) 2019-05-16
EP3391942A1 (en) 2018-10-24
US9765139B2 (en) 2017-09-19
MX2015013668A (es) 2016-06-28
JP2020073503A (ja) 2020-05-14
RS59328B1 (sr) 2019-10-31
MX362922B (es) 2019-02-25
AU2019201129B2 (en) 2020-12-24
CA2907771C (en) 2023-01-10
EP2978498A1 (en) 2016-02-03
SG10201802023RA (en) 2018-05-30
US20160122427A1 (en) 2016-05-05
JP6689189B2 (ja) 2020-04-28
EP2978498B1 (en) 2019-07-03
AU2014241259B2 (en) 2018-12-06
EP2978498A4 (en) 2016-10-05
AU2014241259A1 (en) 2015-10-22
AU2014241259B9 (en) 2018-12-20
CA2907771A1 (en) 2014-10-02
SG11201507875RA (en) 2015-10-29
AU2019201129A1 (en) 2019-03-07
US20140296489A1 (en) 2014-10-02
BR112015024755A2 (pt) 2017-07-18
JP2016514475A (ja) 2016-05-23
US10975138B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
GB2520596B (en) Manufacturing method
GB201309057D0 (en) Method
IL239737A0 (en) Method for protein production
HK1218893A1 (zh) 蛋白質的生產方法
GB201315777D0 (en) Novel method
EP2960338A4 (en) SUGAR SOLUTION PROCESS
GB201309928D0 (en) Method
IL241779A0 (en) Method for protein production
GB201301857D0 (en) Method
GB201313249D0 (en) Method
GB201309654D0 (en) Method
GB201301233D0 (en) Method
GB201300409D0 (en) Method
EP2868476A4 (en) PROCESS FOR PRODUCING PRINTED MEDIA
GB201311385D0 (en) Method
GB201305714D0 (en) Method
GB201310151D0 (en) Novel method
GB201301094D0 (en) Method
GB201314054D0 (en) Method
GB201311389D0 (en) Method
GB201319808D0 (en) Method of producing proteins
GB201314332D0 (en) Method
GB201313412D0 (en) Method
GB201313416D0 (en) Method
GB201312397D0 (en) Method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230323